Whole soy, but not purified daidzein, had a favorable effect on improvement of cardiovascular risks: A 6-month randomized, double-blind, and placebo-controlled trial in equol-producing postmenopausal women

Molecular Nutrition and Food Research

Volumn 58, Issue 4, 2014, Pages 709-717

  Liu, Zhao min ^a   Ho, Suzanne C ^a   Chen, Yu ming ^b   Ho, Stella ^a   To, Kenneth ^a   Tomlinson, Brian ^a   Woo, Jean ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cardiovascular risks; Daidzein; Inflammatory marker; Lipids; Whole soy

Indexed keywords

C REACTIVE PROTEIN; DAIDZEIN; EQUOL; ISOFLAVONE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ANIMAL; ARTERIAL WALL THICKNESS; BLOOD; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; MILK; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SOYBEAN;

AGED; ANIMALS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; EQUOL; FEMALE; HUMANS; ISOFLAVONES; MIDDLE AGED; MILK; POSTMENOPAUSE; RISK FACTORS; SOYBEANS;

EID: 84897053526     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300499     Document Type: Article

References (41)

1. Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J. et al., Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125, e2-e220.
2. Young, D., Camhi, S., Wu, T., Hagberg, J., Stefanick, M., Relationships among changes in C-reactive protein and cardiovascular disease risk factors with lifestyle interventions. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 857-863.
3. de Kleijn, M., van der Schouw, Y., Wilson, P., Grobbee, D. et al., Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S. women: the Framingham study. J. Nutr. 2002, 132, 276-282.
4. Chan, Y., Lau, K., Yiu, K., Li, S. et al., Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am. J. Clin. Nutr. 2007, 86, 938-945.
5. Register, T., Cann, J., Kaplan, J., Williams, J. et al., Effects of soy isoflavones and conjugated equine estrogens on inflammatory markers in atherosclerotic, ovariectomized monkeys. J. Clin. Endocrinol. Metab. 2005, 90, 1734-1740.
6. Clarkson, T., Anthony, M., Morgan, T., Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phyto-estrogens. J. Clin. Endocrinol. Metab. 2001, 86, 41-47.
7. Zhan, S., Ho, S., Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am. J. Clin. Nutr. 2005, 81, 397-408.
8. Sacks, F., Lichtenstein, A., Van Horn, L., Harris, W. et al., Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006, 113, 1034-1044.
9. Jackman, K. A., Woodman, O. L., Chrissobolis, S., Sobey, C. G., Vasorelaxant and antioxidant activity of the isoflavone metabolite equol in carotid and cerebral arteries. Brain Res. 2007, 1141, 99-107.
10. Duncan, A. M., Merz-Demlow, B. E., Xu, X., Phipps, W. R. et al., Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 581-586.
11. Setchell, K. D., Brown, N. M., Lydeking-Olsen, E., The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr. 2002, 132, 3577-3584.
12. Welty, F. K., Lee, K. S., Lew, N. S., Zhou, J. R., Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive, and normotensive postmenopausal women. Arch. Intern. Med. 2007, 167, 1060-1067.
13. Kreijkamp-Kaspers, S., Kok, L., Bots, M. L., Grobbee, D. E. et al., Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am. J. Clin. Nutr. 2005, 81, 189-195.
14. Hooper, L., Kroon, P. A., Rimm, E. B., Cohn, J. S. et al., Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2008, 88, 38-50.
15. O'Leary, D., Polak, J., Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am. J. Cardiol. 2002, 90, 18L-21L.
16. Lim, S., Vos, T., Flaxman, A., Danaei, G. et al., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013, 380, 2224-2260.
17. Setchell, K., SJ, C., Method of defining equol-producer status and its frequency among vegetarians. J. Nutr. 2006, 136, 2188-2193.
18. Chen, Y. M., Ho, S. C., Lam, S. S., Ho, S. S., Woo, J. L., Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J. Clin. Endocrinol. Metab. 2003, 88, 4740-4747.
19. Khaodhiar, L., Ricciotti, H. A., Li, L., Pan, W. et al., Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008, 15, 125-132.
20. Yue-xin, Y., China Food Composition 2002. Institute of Nutrition and Food Safety, Peking University Medical Press, Beijing, P.R. China 2002.
21. Song, T., Barua, K., Buseman, G., Murphy, P., Soy isoflavone analysis: quality control and a new internal standard. Am. J. Clin. Nutr. 1998, 68, 1474S-1479S.
22. Duncan, A. M., Merz-Demlow, B. E., Xu, X., Phipps, W. R. et al., Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 581-586.
23. Wu, J., Oka, J., Ezaki, J., Ohtomo, T. et al., Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause 2007, 14, 866-874.
24. Tormala, R., Appt, S., Clarkson, T., Groop, P. et al., Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone no effect with soy supplementation. Atherosclerosis 2008, 198, 174-178.
25. Liu, P., Zhao, Y., Zhang, Y., Clinical observation of daidzein intervention on serum inflammatory factors in senile patients with coronary heart disease. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006, 26, 42-45.
26. Liu, Z., Chen, Y., Ho, S., Effects of soy intake on glycemic control: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2011, 93, 1092-1101.
27. O'Brien, T., Nguyen, T., Lipids and lipoproteins in women. Mayo Clin. Proc. 1997, 72, 235-244.
28. Clarkson, T., Soy, soy phytoestrogens and cardiovascular disease. J. Nutr. 2002, 132, 566S-569S.
29. Liu, Z., Chen, Y., Ho, S., Effects of soy intake on glycemic control: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2011, 93, 1092-1101.
30. Gianazza, E., Eberini, I., Arnoldi, A., Wait, R., Sirtori, C., A proteomic investigation of isolated soy proteins with variable effects in experimental and clinical studies. J. Nutr. 2003, 133, 9-14.
31. Rice, B. H., Quann, E. E., Miller, G. D., Meeting and exceeding dairy recommendations: effects of dairy consumption on nutrient intakes and risk of chronic disease. Nutr. Rev. 2013, 71, 209-223.
32. Reinwald, S., Akabas, S. R., Weaver, C. M., Whole versus the piecemeal approach to evaluating soy. J. Nutr. 2010, 140, 2335S-2343S.
33. Erdman, J. W., Soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA. Circulation 2000, 102, 2555-2559.
34. Xiao, C., Mei, J., Wood, C., Effect of soy proteins and isoflavones on lipid metabolism and involved gene expression. Front Biosci. 2008, 13, 2660-2673.
35. Zhang, H. P., Zheng, F. L., Zhao, J. H., Guo, D. X., Chen, X. L., Genistein inhibits ox-LDL-induced VCAM-1, ICAM-1 and MCP-1 expression of HUVECs through heme oxygenase-1. Arch. Med. Res. 2013, 44, 13-20.
36. Gilstrap, L. G., Wang, T. J., Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin. Chem. 2012, 58, 72-82.
37. Dong, J., Wang, P., He, K., Qin, L., Effect of soy isoflavones on circulating C-reactive protein in postmenopausal women: meta-analysis of randomized controlled trials. Menopause 2011, 18, 1256-1262.
38. Zhang, B., Chen, Y. M., Huang, L. L., Zhou, X. X. et al., Greater habitual soy food consumption is associated with decreased carotid intima-media thickness and better plasma lipids in Chinese middle-aged adults. Atherosclerosis 2008, 198, 403-411.
39. Chan, Y. H., Lau, K. K., Yiu, K. H., Li, S. W. et al., Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am. J. Clin. Nutr. 2007, 86, 938-945.
40. Hodis, H. N., Mack, W. J., Kono, N., Azen, S. P. et al., Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women. Stroke 2011, 42, 3168-3175.
41. Hodis, H., Mack, W., Atherosclerosis imaging methods: assessing cardiovascular disease and evaluating the role of estrogen in the prevention of atherosclerosis. Am. J. Cardiol. 2002, 89, 19E-27E; discussion 27E.